An interventional study of Avenanthramides in Avenanthramides, sponsored by PepsiCo Global R&D. Completed. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-10.
Sponsored by PepsiCo Global R&D · Not applicable, Interventional, and Basic science
The aim of the proposed study is to examine whether long-term dietary supplementation (8 weeks) of an oat flour cookie rich in avenanthramides (AVA) could enhance blood antioxidant capacity and reduce blood inflammatory markers after a downhill running (DR) protocol among human subjects.
PepsiCo Global R&D is the lead sponsor of 101 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Avenanthramides
Other: Avenanthramides
AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
Mean and SD of plasma concentrations of Creatine Kinase
Time frame: 0-72 hours
Mean and SD of plasma concentrations of TNF-α
Time frame: 0-72 hours
Mean and SD of plasma concentrations of IL-6
Time frame: 0-72 hours
Mean and SD of plasma concentrations of ICAM-1, VCAM-1, NF-κB (P65), NRB, NF-κB binding to DNA, 4-Hydroxynenenol, F2-isoprostane
Time frame: 0-72 hours
No study locations are listed for this record.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PepsiCo Global R&D